Pharmacological approaches to the treatment of diabetic complications

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 8, 2000, Pages 1245-1262

  Costantino, L ^a   Rastelli, G ^a   Gamberini, M C ^a   Barlocco, D ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Advanced glycated end products; Aldose reductase inhibitors; C peptide; Long term diabetic complications; Polyol pathway; Protein kinase C

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; 3',5' DIMETHYL 2 (2 METHYLPHENYL) 4' (NITROMETHYLSULFONYL)ACETANILIDE; 4 [2 (2 HYDROXYETHOXY)ETHYLAMINO] 2 (1H IMIDAZOL 1 YL) 6 METHOXYQUINAZOLINE; 6 [4 (4 CHLOROPHENYLSULFONYLAMINO) 1 (3 PYRIDYLMETHYL) 2 PYRROLIDINYL] 5 HEXENOIC ACID; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALDOSE REDUCTASE INHIBITOR; ALT 462; ALT 486; ALT 766; AMINOGUANIDINE; ANTIDIABETIC AGENT; C PEPTIDE; CARBOXYLIC ACID; DAFLON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EPALRESTAT; FIDARESTAT; HISTIDINE; HYDANTOIN DERIVATIVE; IDITOL DEHYDROGENASE; LEUCINE; MINALRESTAT; OBP 9195; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYOL; PONALRESTAT; PROTEIN KINASE C INHIBITOR; PYRIDORIN; PYRIDOXAMINE; RANIRESTAT; RISARESTAT; RUBOXISTAURIN; SDI 157; SDI 158; SORBINIL; TOLRESTAT; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZENARESTAT; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; HYPERGLYCEMIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATENT; RAT; REVIEW;

EID: 0033887658     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.8.1245     Document Type: Review

References (110)

1. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The diabetes control and complications trial
2. Insulin resistance, impaired glucose tolerance and non-insulin dependent diabetes, pathological mechanisms and treatment: Current status and therapeutic possibilities
3. Antidiabetic agents. Recent advances in their molecular and clinical pharmacology
4. New hypoglycaemic agents
5. Glucose complications: Why is glucose potentially toxic?
6. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications
7. Experimental diabetic neuropathy: An update
8. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
9. Endothelin: Emerging role in diabetic vascular complications
10. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats
11. Metabolism of fructose-3-phosphate in the diabetic rat lens
12. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway
13. Formation of reactive intermediates from Amadori compounds under physiological conditions
14. Role of polyol pathway in nonenzymatic glycation
15. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway
16. New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications
17. Molecular modeling of the aldose reductase-inhibitor complex based on X-ray crystal structure and studies with single-site-directed mutants
18. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor Zopolrestat
19. A specificity pocket inferred from the crystal structures of complexes of aldose reductase with the pharmaceutically important inhibitors Tolrestat and Sorbinil
20. Benzothiazole aldose reductase inhibitors
21. A perspective of aldose reductase inhibitors
22. N-substituted spirosuccinimide, spiropyridazine, spiroazetidine and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2
23. Novel, highly potent aldose reductase inhibitors: R-(-)-2-(4-bromo- 2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a] pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5-tetrone (AS-3201) and its congeners
24. Molecular biology of aldose reductase
25. Catalysis of reduction of carbohydrate 2-oxoaldehyde (osones) by mammalian aldose reductase and aldehyde reductase
26. Increased levels on methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: Aldose reductase, glyoxalase I and glyoxalase II- research study
27. Design and synthesis of novel inhibitors of aldose reductase for the treatment of diabetic complications
28. The PPARs: From orphan receptors to drug discovery
29. Aldose reductase inhibitors: Recent developments
30. Synthesis and aldose reductase inhibitory activity of a new series of 5[[2-(omega-carboalkoxy)aryl]methylene]-4-oxo-2-thioxothiazolidine derivatives
31. Binding of aldose reductase inhibitors: Correlation of crystallographic and mass spectrometric studies
32. Synthesis and biological activity of aldose reductase inhibitors with Michael acceptor substituents
33. Synthesis and biological evaluation of irreversible inhibitors of aldose reductase
34. Phenylsulfonylnitrometanes as potent irreversible inhibitors of aldose reductase
35. Selective irreversible inhibitors of aldose reductase
36. Aldose reductase inhibitors: The end of an era or the need for different trial designs?
37. Zopolrestat
38. Effect of aldose reductase inhibitors on the progression of nerve damage
39. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism
40. Future prevention and treatment of diabetic neuropathy
41. Pathology and pathogenesis of diabetic neuropathy
42. Nitric oxide and vascular responses in Type I diabetes
43. The aldose reductase inhibitor, Zopolrestat, amplifies blood vessel relaxation by inhibition of cGMP-specific phosphodiesterase
44. Effect of a novel aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats
45. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches
46. Can diabetic neuropathy be prevented by ACE inhibitors?
47. AS3201
48. Hyperglycemic pseudohypoxia and diabetic complications
49. Inhibition of Sorbitol dehydrogenase. Effects on vascular and neural dysfunctions in sreptozotocin-induced diabetic rats
50. Sorbitol-accumulating pyrimidine derivatives
51. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: A prevention study
52. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm
53. Advanced glycation end products and hyperglycemia in the pathogenesis of diabetic complications
54. Negative consequences of glycation
55. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs
56. Mitogen-activated protein kinases as glucose transducers for diabetic complications
57. Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases
58. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo
59. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats
60. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
61. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy
62. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
63. Glycation and diabetic complications
64. Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions
65. Accumulation of alpha-oxoaldehydes during oxidative stress: A role in cytotoxicity
66. Kinetic and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions
67. The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins
68. Biological effects of aminoguanidine: An update
69. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo
70. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
71. Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links
72. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end products: Comparison with aminoguanidine
73. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs)
74. Synthesis and antihypertensive activity of 5-substituted 4-amino-3-hydrazino-4H-1,2,4-triazoles and the corresponding 3-(2,6-dichlorobenzylidenehydrazino) derivatives
75. Chronic dosing with aminoguanidine and novel advanced glycosilation end product-formation inhibitors ameliorates crosslinking of tail tendon collagen in STZ-induced diabetic rats
76. Progression of nephropathy in spontaneous diabetic rats is prevented by OBP-9195, a novel inhibitor of advanced glycation
77. Inhibitory effects of tenilsetam on the Maillard reaction
78. The cognition-enhancer drug tenilsetam is an inhibitor of protein cross-linking by advanced glycosylation
79. Novel inhibitors of advanced glycation end products
80. Synthesis and investigation of effects of 2-(4-(((arylamino)carbonyl)amino)-phenoxyl)-2-methylpropionic acids on the affinity of hemoglobin for oxygen: Structure-activity relationships
81. Oxidative stress and diabetic vascular complications
82. Negative consequences of glycation
83. Glycation, glycoxidation and cross-linking of collagen by glucose
84. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy
85. Normalization of diacylglycerol-protein kinase C activation by Vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels
86. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway
87. d-α-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with Protein kinase C inhibition and is independent of its antioxidant properties
88. Oxidative stress and glycemic regulation
89. The impact of plant flavonoids on mammalian biology: Implications for immunity, inflammation and cancer
90. Role of oxidative stress in development of complications in diabetes
91. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and Rutin
92. The effect of flavonoid treatment on the glycation and antioxidant status in Type I diabetic patients
93. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide
94. The influence of human C-peptide on renal function and glucose utilization in Type I (insulin-dependent) diabetic patients
95. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of Type I (insulin-dependent) diabetic patients
96. C-peptide improves autonomic nerve function in patients with Type 1 diabetes
97. New aspects on biological activity of C-peptide in IDDM patients
98. Role of C-peptide in human physiology
99. + ATP-ase activity in synergism with neuropeptide Y
100. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus
101. Activation of endothelial nitric oxide synthase (eNOS) by C-peptide
102. Protein kinase C activation and the development of diabetic complications
103. Protein kinases and phosphatases: Structural biology and synthetic inhibitors
104. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitors
105. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4, 9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrr olo[3,4-h][1,4,13]oxa=diazacyclohexadecene-1,3-(2H)-dione (LY333531) and kinase C beta